<SEC-DOCUMENT>0001193125-24-003868.txt : 20240108
<SEC-HEADER>0001193125-24-003868.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108070834
ACCESSION NUMBER:		0001193125-24-003868
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240108
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mereo BioPharma Group plc
		CENTRAL INDEX KEY:			0001719714
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38452
		FILM NUMBER:		24518305

	BUSINESS ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF
		BUSINESS PHONE:		4403330237300

	MAIL ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mereo Biopharma Group plc
		DATE OF NAME CHANGE:	20171016
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d100759d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mreo="http://www.mereobiopharma.com/20240108" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-01-08_to_2024-01-08">00-0000000</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2024-01-08_to_2024-01-08" name="dei:AmendmentFlag" contextRef="duration_2024-01-08_to_2024-01-08">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2024-01-08_to_2024-01-08" name="dei:EntityCentralIndexKey" contextRef="duration_2024-01-08_to_2024-01-08">0001719714</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_NoTradingSymbolFlag_duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember" name="dei:NoTradingSymbolFlag" contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember">true</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mreo-20240108.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2024-01-08_to_2024-01-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001719714</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-08</xbrli:startDate> <xbrli:endDate>2024-01-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001719714</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mreo:AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-08</xbrli:startDate> <xbrli:endDate>2024-01-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001719714</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mreo:OrdinarySharesNominalValue0.003PerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-08</xbrli:startDate> <xbrli:endDate>2024-01-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p><p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap">FORM&#160;<ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-01-08_to_2024-01-08" id="Fact_1">8-K</ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-01-08_to_2024-01-08" format="ixt:date-monthname-day-year-en" id="Fact_0">January&#160;8, 2024</ix:nonNumeric></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityRegistrantName">MEREO BIOPHARMA GROUP PLC</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityFileNumber">001-38452</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber" id="Fact_2">Not Applicable</span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityAddressAddressLine1">4<sup style="font-size:75%; vertical-align:top">th</sup>&#160;Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityAddressAddressLine2">One Cavendish Place</ix:nonNumeric>,</p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityAddressCityOrTown">London</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-01-08_to_2024-01-08" id="Fact_3">W1G&#160;0QF</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">+<ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:CountryRegion">44</ix:nonNumeric>-<ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:CityAreaCode">333</ix:nonNumeric>-<ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:LocalPhoneNumber">023-7300</ix:nonNumeric></span></span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"><p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <span style="white-space:nowrap">Form&#160;8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table><p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to <span style="white-space:nowrap">Rule&#160;14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table><p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to <span style="white-space:nowrap">Rule&#160;14d-2(b)&#160;under</span> the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table><p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to <span style="white-space:nowrap">Rule&#160;13e-4(c)&#160;under</span> the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title&#160;of&#160;each&#160;class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name&#160;of&#160;each&#160;exchange</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" id="Fact_4">American Depositary Shares, each representing five Ordinary Shares, par value &#163;0.003 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" id="Fact_5">MREO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" format="ixt-sec:exchnameen" id="Fact_6">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember" id="Fact_7">Ordinary Shares, nominal value &#163;0.003 per share</ix:nonNumeric>*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top">*</td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember" format="ixt-sec:exchnameen" id="Fact_8">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr> </table><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top">*</td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.</p></td></tr> </table><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or <span style="white-space:nowrap">Rule&#160;12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p><p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;<ix:nonNumeric contextRef="duration_2024-01-08_to_2024-01-08" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p><p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure.</p></td></tr></table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Press Release </span></p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;8, 2024, Mereo BioPharma Group plc (the &#8220;Company&#8221;) issued a press release providing an update on its pipeline programs as well as an update on recent corporate developments. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span></p><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Domestic Issuer Status </span></p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will begin to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission, which are more detailed and extensive in certain respects, and which must be filed more promptly, than the forms available to a &#8220;foreign private issuer&#8221; as defined in Rule 405 under the Securities Act of 1933, as amended. Prior to January&#160;1, 2024, the Company qualified as a foreign private issuer.</p><p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Disclosure Channels to Disseminate Information </span></p><p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company announces material information to the public about the Company, its potential product candidates and its pipeline and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.mereobiopharma.com) and the investor relations section of its website (www.mereobiopharma.com/investors/overview), in order to achieve broad, <span style="white-space:nowrap">non-exclusionary</span> distribution of information to the public. The Company encourages investors and others to review the information it makes public in these locations, as such information could be deemed to be material information. This list of communication channels may be updated from time to time.</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company&#8217;s filings under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits.</p></td></tr></table><p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:98%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description of Exhibit</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d100759dex991.htm">Press Release, dated January&#160;8, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr></table></div></div><p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p><p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:44%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">MEREO BIOPHARMA GROUP PLC</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: January&#160;8, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christine Fox</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Christine Fox</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d100759dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Exhibit 99.1 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Phase&nbsp;3 portion of Orbit Study and Phase&nbsp;3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by
partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase&nbsp;2 data expected in 2024</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Alignment on design for single, global Phase 3 study of alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD)
following additional interactions with U.S. FDA in 2H 2023</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signs global licensing deal for development and commercialization of
leflutrozole</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Reiterates previous cash runway guidance; current cash expected to fund operations into 2026</I> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>London, January&nbsp;8, 2024</B>&nbsp;&#150; Mereo BioPharma Group plc (NASDAQ: MREO) (&#147;Mereo&#148; or the &#147;Company&#148;), a clinical-stage
biopharmaceutical company focused on rare diseases, today provided an update on its pipeline programs as well as an update on recent corporate developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2023 was a year of tremendous progress for Mereo. Key milestones in the development of setrusumab for the treatment of OI included positive data from
the Phase 2 portion of the Orbit study, and initiation of the Phase 3 portion of the Orbit study and Phase&nbsp;3 Cosmic study by our partner, Ultragenyx,&#148; said Dr.&nbsp;Denise Scots-Knight, Chief Executive Officer of Mereo. &#147;In addition,
we significantly advanced the development of alvelestat, gaining valuable clarity on the regulatory path with both the FDA and EMA. If the proposed Phase 3 study is successful, it could support submissions for full regulatory approvals for this <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapy addressing a major unmet medical need in <FONT STYLE="white-space:nowrap">Alpha-1</FONT> Antitrypsin Deficiency-associated Lung Disease. These
developments are expected to further support our ongoing partnering activities for alvelestat. We look forward to providing further updates on both setrusumab and alvelestat during the remainder of the year. With a cash runway into 2026 and several
potential important value inflection points on the horizon in 2024, we believe that Mereo remains well positioned for long-term growth and success.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Pipeline Progress </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Setrusumab (UX143) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enrollment in the Phase 3 portion of the Global Phase 2/3 Orbit study led by Mereo&#146;s partner, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), was initiated
in <FONT STYLE="white-space:nowrap">mid-2023</FONT> and the study is expected to be fully enrolled around the end of the first quarter of 2024. The pivotal Phase 3 portion of the Orbit study will include up to 195 patients aged 5 to &lt;26 years
randomized 2:1 to receive setrusumab or placebo, with a primary efficacy endpoint of annualized clinical fracture rate excluding fingers, toes, skull and face. Additionally, Cosmic, a Global Phase 3 open-label, randomized, active-controlled study in
approximately 65 patients aged 2 to &lt;7 years evaluating setrusumab compared to intravenous bisphosphonates on reduction in total fracture rate, including morphometric vertebral fractures, was initiated in the second half of 2023 and is
anticipated to be fully enrolled in the first half of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent data reported in October 2023, from the 24 patients enrolled in the Phase 2 portion of
the Orbit study with at least 6 months of treatment, showed that treatment with setrusumab reduced the annualized fracture rate by 67%. This reduction was associated with continuing large and meaningful improvements in bone mineral density (BMD).
Setrusumab was well tolerated with no drug related serious adverse events (SAE&#146;s) reported and no reports of drug-related hypersensitivity. Additional data from the Phase 2 portion of the Orbit study are expected during 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), setrusumab would be the first FDA and <FONT
STYLE="white-space:nowrap">EMA-approved</FONT> treatment for Osteogenesis Imperfecta (OI). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has received guidance from the EMA and European
Health Technology Assessment (HTA) agencies on its approach to the design and delivery of a post-Marketing Authorization Evidence Generation Plan (&#147;SATURN&#148;) and continues to interact with key decision-makers at European and national levels
in Mereo&#146;s commercial territory to prepare the markets should setrusumab receive regulatory approval. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alvelestat <FONT STYLE="white-space:nowrap">(MPH-966)</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has continued its interactions with the Division of Pulmonology, Allergy and Critical Care (DPACC) and the Division of Clinical Outcome Assessment
(DCOA) of the FDA regarding the use of a Patient Reported Outcome (PRO) instrument as a potential primary endpoint in its planned Phase 3 study of alvelestat for the treatment of <FONT STYLE="white-space:nowrap">Alpha-1</FONT> Antitrypsin
Deficiency-associated Lung Disease <FONT STYLE="white-space:nowrap">(AATD-LD).</FONT> These interactions followed an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting for the Company&#146;s
ASTRAEUS study in the first quarter of 2023, at which the FDA and the Company discussed the potential use of the St George&#146;s Respiratory Questionnaire (SGRQ) Total Score and/or SGRQ Activity domain as the primary endpoint in a Phase 3 study
which, if successful, could support submissions for full approval in the U.S. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the third quarter of 2023, the Company held an additional meeting with
the FDA (DPACC and the DCOA) and analyzed additional data from the <FONT STYLE="white-space:nowrap">investigator-led</FONT> Phase 2 ATALANTa study, which was funded by the National Center for Advancing Translational Sciences (NCATS) through the
National Institutes of Health (NIH)-Industry Program for discovering new therapeutic uses for existing molecules, and led by Professor Mark Dransfield from the University of Alabama at Birmingham. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from both the ATALANTa and ASTRAEUS studies support the use of the SGRQ Total Score as the primary endpoint in the proposed Phase 3 study based on
benefits observed in patients with the severe Pi*ZZ phenotype, including those who are in the early stages of the lung disease. In some countries, these patients are currently not eligible for, or not treated with, augmentation therapy. Following
additional FDA interactions in the fourth quarter of 2023, subsequent to the DCOA meeting, the Company has aligned on a Phase 3 study design using SGRQ Total Score as the primary endpoint with a functional assessment as a key secondary endpoint
which, if the study is successful, is expected to support submissions for full regulatory approval in the U.S. Inclusion of patients with earlier and later stage lung disease progression in the planned registrational study could increase the
addressable patient population for alvelestat. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the Company has received guidance from the EMA on the primary endpoint for its Phase 3 clinical
trial of alvelestat for the treatment of <FONT STYLE="white-space:nowrap">AATD-LD.</FONT> The EMA has indicated that lung density by computed tomography (CT) scan with a relaxed p value (p&lt;0.1) may be sufficient for full approval if the study is
successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company remains engaged with multiple potential partners for the development and potential commercialization of alvelestat and expects to
provide further details on these efforts in 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leflutrozole </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recently entered into an exclusive global license agreement with ReproNovo SA (the &#147;License Agreement&#148;) for the development and
commercialization of leflutrozole, a <FONT STYLE="white-space:nowrap">non-steroidal</FONT> aromatase inhibitor. Under the terms of the License Agreement, ReproNovo, a reproductive medicine company, is responsible for all future development and
commercialization of leflutrozole. Mereo received an upfront payment and will be eligible to receive up to $64.25&nbsp;million in future clinical, regulatory and commercial milestones as well as tiered
<FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalties on global annual net sales of leflutrozole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Runway Guidance and Financial
Reporting Update </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company continues to expect its existing cash and short-term deposits, excluding income from existing or potential partnerships,
will enable it to fund its currently committed clinical trials, operating expenses and capital expenditure requirements into 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective
January&nbsp;1, 2024, the Company began complying with and reporting under the SEC rules and Nasdaq listing requirements applicable to U.S. domestic filers. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Mereo BioPharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease
product candidates, setrusumab for the treatment of Osteogenesis Imperfecta (OI) and alvelestat primarily for the treatment of severe <FONT STYLE="white-space:nowrap">Alpha-1</FONT> Antitrypsin Deficiency-associated Lung Disease <FONT
STYLE="white-space:nowrap">(AATD-LD).</FONT> The Company&#146;s partner, Ultragenyx Pharmaceutical Inc., initiated a pivotal Phase 2/3 pediatric study in young adults (5 to &lt;26 years old) for setrusumab in OI and a Phase 3 study in pediatric
patients (2 to &lt;7 years old) in <FONT STYLE="white-space:nowrap">mid-2023.</FONT> The partnership with Ultragenyx includes potential milestone payments of up to $245&nbsp;million (following the recent $9&nbsp;million milestone) and royalties to
Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received orphan designation for OI from the EMA and FDA,
PRIME designation from the EMA and has pediatric disease designation from the FDA. Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD, Fast Track designation from the FDA, and two Phase 2 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies have been completed in North America and Europe. In addition to the rare disease programs, Mereo has two oncology product candidates in clinical development. Etigilimab (anti-TIGIT)
has completed a Phase 1b/2 basket study evaluating its safety and efficacy in combination with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> in a range of tumor types including three rare tumors and
three gynecological carcinomas&#151;cervical, ovarian, and endometrial and is in an ongoing Phase 1b/2 investigator led study at the MD Anderson Cancer Center in clear cell ovarian cancer; navicixizumab, for the treatment of late line ovarian
cancer, has completed a Phase 1 study and has been partnered with OncXerna Therapeutics, Inc. in a global licensing agreement that includes payments of up to $300&nbsp;million in milestones and royalties. Mereo has entered into an exclusive global
license agreement with ReproNovo SA for the development and commercialization of leflutrozole, a <FONT STYLE="white-space:nowrap">non-steroidal</FONT> aromatase inhibitor. Under the terms of the agreement, ReproNovo, a reproductive medicine company,
is responsible for all future development and commercialization of leflutrozole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on Mereo BioPharma, please visit
www.mereobiopharma.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; that involve substantial risks and uncertainties. All statements other than statements of
historical fact contained herein are forward-looking statements within the meaning of Section&nbsp;27A of the United States Securities Act of 1933, as amended, and Section&nbsp;21E of the United States Securities Exchange Act of 1934, as amended.
Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words &#147;believe,&#148;
&#147;expect,&#148; &#147;anticipate,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;foresee,&#148; &#147;should,&#148; &#147;would,&#148; &#147;could,&#148; &#147;may,&#148; &#147;estimate,&#148; &#147;outlook&#148; and similar expressions,
including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company&#146;s current expectations, beliefs and assumptions concerning
future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the
Company will be those that it anticipates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s forward-looking statements involve known and unknown risks and uncertainties some of
which are significant or beyond its control and assumptions that could cause actual results to differ materially from the Company&#146;s historical experience and its present expectations or projections. Such risks and uncertainties include, among
others, the uncertainties inherent in the clinical development process; the Company&#146;s reliance on third parties to conduct and provide funding for its clinical trials; the Company&#146;s dependence on enrollment of patients in its clinical
trials; and the Company&#146;s dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company&#146;s business, including those described in the &#147;Risk
Factors&#148; section of its latest Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in the Company&#146;s subsequent filings with the
Securities and Exchange Commission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our
forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mereo BioPharma Contacts:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mereo</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+44 (0)333 023 7300</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denise Scots-Knight, Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christine Fox, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Burns McClellan (Investor Relations Adviser to Mereo)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>+01 646 930 4406</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lee Roth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>investors@mereobiopharma.com</U></P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mreo-20240108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.8 -->
<!-- Creation date: 1/8/2024 6:14:42 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:mreo="http://www.mereobiopharma.com/20240108"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:us-types="http://fasb.org/us-types/2023"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.mereobiopharma.com/20240108"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" namespace="http://fasb.org/us-types/2023" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mreo-20240108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mreo-20240108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mreo-20240108_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mreo_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mreo_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" name="AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="mreo_OrdinarySharesNominalValue0.003PerShareMember" name="OrdinarySharesNominalValue0.003PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>mreo-20240108_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.8 -->
<!-- Creation date: 1/8/2024 6:14:44 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mreo-20240108.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="mreo-20240108.xsd#mreo_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="mreo_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="mreo_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" xlink:type="locator" xlink:label="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_OrdinarySharesNominalValue0.003PerShareMember" xlink:type="locator" xlink:label="mreo_OrdinarySharesNominalValue0.003PerShareMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:type="locator" xlink:label="dei_CountryRegion" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="mreo_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mreo_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" order="24" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mreo_OrdinarySharesNominalValue0.003PerShareMember" order="25" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.071" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.171" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_CountryRegion" order="31.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.011" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.021" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="34.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="35.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="36.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="37.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="42.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="43.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="45.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="47.001" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mreo-20240108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.8 -->
<!-- Creation date: 1/8/2024 6:14:42 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="mreo-20240108.xsd#mreo_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="mreo_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mreo_DocumentAndEntityInformationTable" xlink:to="mreo_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="mreo_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="mreo_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="mreo-20240108.xsd#mreo_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="mreo_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="mreo_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="mreo_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="mreo_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="mreo-20240108.xsd#mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" xlink:type="locator" xlink:label="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" xlink:to="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Shares, each representing five Ordinary Shares, par value &#163;0.003 per share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Depositary Shares, each representing five Ordinary Shares, par value &#163;0.003 per share [Member]</link:label>
    <link:loc xlink:href="mreo-20240108.xsd#mreo_OrdinarySharesNominalValue0.003PerShareMember" xlink:type="locator" xlink:label="mreo_OrdinarySharesNominalValue0.003PerShareMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mreo_OrdinarySharesNominalValue0.003PerShareMember" xlink:to="mreo_OrdinarySharesNominalValue0.003PerShareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="mreo_OrdinarySharesNominalValue0.003PerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary Shares, nominal value &#163;0.003 per share* [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="mreo_OrdinarySharesNominalValue0.003PerShareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares, nominal value &#163;0.003 per share* [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line 2</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Address Line 2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:type="locator" xlink:label="dei_CountryRegion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CountryRegion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Country Region</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CountryRegion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Country Region</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Trading Symbol Flag</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mreo-20240108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - Donnelley Financial Solutions, Inc. -->
<!-- CTU Version: 72.0.8 -->
<!-- Creation date: 1/8/2024 6:14:42 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mreo-20240108.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="mreo_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="mreo_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="mreo_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationTable" xlink:to="mreo_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0.01" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" xlink:type="locator" xlink:label="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="mreo-20240108.xsd#mreo_OrdinarySharesNominalValue0.003PerShareMember" xlink:type="locator" xlink:label="mreo_OrdinarySharesNominalValue0.003PerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mreo_OrdinarySharesNominalValue0.003PerShareMember" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.071" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.171" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:type="locator" xlink:label="dei_CountryRegion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_CountryRegion" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.021" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mreo_DocumentAndEntityInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140318119531648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mreo_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEREO BIOPHARMA GROUP PLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">4th&#160;Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">One Cavendish Place<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">London<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">W1G&#160;0QF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">023-7300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001719714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember', window );">American Depositary Shares, each representing five Ordinary Shares, par value &#163;0.003 per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mreo_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares, each representing five Ordinary Shares, par value &#163;0.003 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MREO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mreo_OrdinarySharesNominalValue0.003PerShareMember', window );">Ordinary Shares, nominal value &#163;0.003 per share* [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mreo_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Ordinary Shares, nominal value &#163;0.003 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mreo_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mreo_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mreo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mreo_OrdinarySharesNominalValue0.003PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mreo_OrdinarySharesNominalValue0.003PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d100759d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mreo="http://www.mereobiopharma.com/20240108"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mreo-20240108.xsd" xlink:type="simple"/>
    <context id="duration_2024-01-08_to_2024-01-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719714</identifier>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719714</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mreo:AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001719714</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mreo:OrdinarySharesNominalValue0.003PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2024-01-08_to_2024-01-08"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag
      contextRef="duration_2024-01-08_to_2024-01-08"
      id="Hidden_dei_AmendmentFlag_duration_2024-01-08_to_2024-01-08">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-01-08_to_2024-01-08"
      id="Hidden_dei_EntityCentralIndexKey_duration_2024-01-08_to_2024-01-08">0001719714</dei:EntityCentralIndexKey>
    <dei:NoTradingSymbolFlag
      contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember"
      id="Hidden_dei_NoTradingSymbolFlag_duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember">true</dei:NoTradingSymbolFlag>
    <dei:DocumentType contextRef="duration_2024-01-08_to_2024-01-08" id="Fact_1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-01-08_to_2024-01-08" id="Fact_0">2024-01-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-01-08_to_2024-01-08">MEREO BIOPHARMA GROUP PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-01-08_to_2024-01-08">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-01-08_to_2024-01-08">001-38452</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-01-08_to_2024-01-08">4th&#160;Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-01-08_to_2024-01-08">One Cavendish Place</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-01-08_to_2024-01-08">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-01-08_to_2024-01-08" id="Fact_3">W1G&#160;0QF</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2024-01-08_to_2024-01-08">GB</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="duration_2024-01-08_to_2024-01-08">44</dei:CountryRegion>
    <dei:CityAreaCode contextRef="duration_2024-01-08_to_2024-01-08">333</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-01-08_to_2024-01-08">023-7300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-01-08_to_2024-01-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-01-08_to_2024-01-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-01-08_to_2024-01-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-01-08_to_2024-01-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember"
      id="Fact_4">American Depositary Shares, each representing five Ordinary Shares, par value &#xa3;0.003 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember"
      id="Fact_5">MREO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember"
      id="Fact_6">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember"
      id="Fact_7">Ordinary Shares, nominal value &#xa3;0.003 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="duration_2024-01-08_to_2024-01-08_us-gaap-StatementClassOfStockAxis_mreo-OrdinarySharesNominalValue0.003PerShareMember"
      id="Fact_8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-01-08_to_2024-01-08">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-01-08_to_2024-01-08">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MNXM[\42QO'N8"%@QZ0+/8XK<+Q9;ZH?K-9%YE:5[N 7_BVRL=09D38 -LHV
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ $#DH6)>*NQS     $P(
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MB^$_7G\!4$L! A0#%     @ $#DH6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  0.2A8/6YV5.X
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ! Y*%B7BKL<P    !,"   +
M      "  4 0  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ! Y*%@<.&7J/P$
M #P"   /              "  2D1  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  0.2A8)!Z;HJT   #X 0  &@              @ &5$@  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  0.2A899!YDAD!  #/
M P  $P              @ %Z$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  #$%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>26</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d100759d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="d100759d8k.htm">d100759d8k.htm</File>
    <File>mreo-20240108.xsd</File>
    <File>mreo-20240108_def.xml</File>
    <File>mreo-20240108_lab.xml</File>
    <File>mreo-20240108_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d100759d8k.htm": {
   "nsprefix": "mreo",
   "nsuri": "http://www.mereobiopharma.com/20240108",
   "dts": {
    "inline": {
     "local": [
      "d100759d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mreo-20240108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "mreo-20240108_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mreo-20240108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mreo-20240108_pre.xml"
     ]
    }
   },
   "keyStandard": 26,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 33,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-01-08_to_2024-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d100759d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-01-08_to_2024-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d100759d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "mreo_AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mereobiopharma.com/20240108",
     "localname": "AmericanDepositarySharesEachRepresentingFiveOrdinarySharesParValue0.003PerShareMember",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depositary Shares, each representing five Ordinary Shares, par value \u00a30.003 per share [Member]",
        "terseLabel": "American Depositary Shares, each representing five Ordinary Shares, par value \u00a30.003 per share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "terseLabel": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "terseLabel": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "terseLabel": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "terseLabel": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "mreo_DocumentAndEntityInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mereobiopharma.com/20240108",
     "localname": "DocumentAndEntityInformationTable",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "mreo_DocumentAndEntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mereobiopharma.com/20240108",
     "localname": "DocumentAndEntityInformationLineItems",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "mreo_OrdinarySharesNominalValue0.003PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mereobiopharma.com/20240108",
     "localname": "OrdinarySharesNominalValue0.003PerShareMember",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares, nominal value \u00a30.003 per share* [Member]",
        "terseLabel": "Ordinary Shares, nominal value \u00a30.003 per share* [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mereobiopharma.com//20240108/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-24-003868-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-003868-xbrl.zip
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MVU3BSIENJ6C7,RF\^53A3"IQM<"Z5)15PTS?HHC'U@"_M#"RV9!.^UUR#0C
MP#$*XO! S1OYGA!^C\)T:D @DGRXWVH=S:N])4'>3%!&\A-.GFU%9_;@@)]F
MAP?\R8Z/A)G5QYO(9W8*6HV]&,0SJWZXV+?C[)/NV0UI-.M5J+@\?'J#]BM#
M^U:836HPD@M0G: __1\'U].Q0=-V<#E0+S4+4]0[+5IQ&HEEF.(_M]2=H']I
MNXU6O6I;W,VZ/6^"\@T+RK5DJ/]Q8[S9&X0.@;SJ]S'+_*,(S%+@ A,J;H8+
MB4 \8CG6$C*OTMCI[=HG(V1)!\^5-=OPF[1]I])VKE3$Y)O,;4'FFJS2VG&W
M('-QPRO+W*9CPXQK:N,O)B&""Q=NJ4,%D01E,-J%,=BWO[G",.=M=\7V5VI7
MR*8L&&M1VO$55[[N\/"SA:SHVT]&W:']YN*IF)=9GGPJ0U]W$3,^X/K:RY?V
M@.W;1"WF$.Z57(1R%ENZUYY%$1#0#NXP8[1F3.<WNJELT>)B;(<G3J-GU,R6
M3G]OYT3L=#VS5>HD79!I'\0V428()-P\GO9#^KA4EO24U@NI)/?8&T'8-8],
MIR3$TX]88VU_=3L[0A;-9>XH_W<ZD7NESL7-Z=4WSNE$:A('W&SS_JX8/K>S
M$T82KW]/)^,=6$_PMR^I\NB?Q!!&+JC\RC3Y5+1Y_4T);O*6CG0:]DN=.4T5
MV+?7T5;_]3I"]$K=?@NRN^:$KR23!T^5R<?R:$^/FK_G/%JC.$NV'+ OGH;"
MS=& #J*MA2^37J2)"/P)GL0!Z 8V5T(>N!Z:%(D/SJE9[8XS)@M](VB%/(*G
MZHLGALX##[-FC/0FQ#4;"*#%K^!U,[-W>F;!GBL"HP(1Q$X'9"#% W# %:,0
M%_&I(A[K\\">6,JLDM;WR/S!R.EYR";9P8K[1V:E-*G,S8&G$ \\X5[N==)X
MC5XE79Y:[43F\N83$C&;-]=^AM;J5C=]9:!J=IF4.J?%DV$Y47BV^YF[^Y(.
M/YK^NK:[U5+0[PI2T-MC%H"[_PA<<>-2(?;YW#Z5(2";^2#T@.Q F'1II)BI
M!8R,=\/@S83<J 5[F8C1(-B7/\'.C:Y *0F /BB1[)XK> _DA08NKL92UVR,
MQ,IX1Z%'I:?L/ACOT5QM<X?N)H'\7)ZZND4@C._2,=O3OT]?B-A,=OF'NQK%
M[AC+[QO[>\;F]A@P'&RN_T GZN\=NV-NF%IG< N$;/]T:/X[2L@,QSF#7WOI
M"VQ^#&_&<18L^CU^..D<'%@[P?O5NI,]=T1>TP5Z+!EG?:(;-HA\NY'O[ /Y
MP)7K"Q5)-N.R/.JQO-N$4I]GL/G>!C?+YZY9(E2*W("^IJ"CE^VD7422&3\8
M"!"!=NOG-4F\"DC1Y01E<H&7 9-?N+@VMP$3L*%12$+?)3NHN'&3;:-^U$U,
M.#PY1[O@=:D(+  EH1F:C(=F38/9=QN0*/3,H3=[4CSD(4/5A'4&DHX4^F8/
M@'W\S-66#*6<)(?A&'AP]\P7(499JDI.H"1,MV?F^T=G4&L*EM/#9D_'0][C
MFAP>5ATT4L8KRM\A@AWB[M+EWM9!Y;?JLJES-N(C+(/3!P$O@"@2N^Q., :-
MU.O@"B.'&!S@3\!L]L!'"9#9?3P\9_T.(-7>VZ',&>'$C3&2JY( V@0BGZNW
M5>(EX^-V?&C!U32R,74RSC,VF?H7T\.#Y3A/#S$.&8%) AAI"C39<\K&25*8
M L;X"30;Y8@\O.! J[*I8E\?14K#H,QP/-L0('@4:A_<-0V=QKN$D41Z#QT8
M,P+CIXGLH#T$I85'->X1SG94L2@51"@$XXV%6SCC^*1LQ&9D'+TJN08N2^PT
M)^-.(N,Z,TE_1@ B<X4#-D"*B5L<,;P0PE-=3KK XH#Y"D<'/RN&*10@]#Q(
M[]Q^?>0#B> GNU AW<C(,_09U0.XB7HP.D)[ F+WS)R4K8(4>&^UV0,IA1?!
M5$.X[G'4BA;C.2V*/]BSQ- '= G\&8+F'@#>R3V5G&FC(D<,W.'L>0B[!_XI
MTI33M+A28D<#'GM\'RW0"YY,#FWI$8T'U@.OG)&=XOOG=TVW^"(/[D'V33#B
MQSMG5)S:P"/2>FE3M:0%51/@L=QS]K"+#"#&%S."Z0XY6!32DX)ZY>6*'Z*"
M"AL# Y$/(%Q)F.VA$N.]*"5NT8Q7218K^#<$(+(9,)4.5DVGT^ < S$ FN7'
MM%&P9"/ZE:F$]=SH'C![OHAW&1FMH")06]GWH#_?0QWF,="TYI0$/!0A%2D%
M$XFY(QQ1;@L3IA.L)([H!!NP%AO"15"'1(-XF%'#YR/:H[$M2<R/-T!U;C4J
M>K<$'=LT+?(,!Z"<S/U4H'(^1NI\P$PR+<KHD/28D;M(!EP-8^NCAB J)FZ?
MSDIB+=#.),8!XW6(LD.AF#GMEX^R#U;,)&5M1<ZKRU9.7+MR>DO! P=HJ:CW
M3^@T ;3/:0\TB.G*=$YU(I_EA2.;7FP #[T)26^PQH,[(GO89E9M)-HJM89V
MY,M-HAE%6C\[SG*:2!Q1#Y2 "5>Q-NWKV.(:1Q1G4/3+Z*Q0Z?GQ<4ND=< "
M)HW<9.YK(#YT$(%4(^:,!%K:R^!IN"RTMR<9WO0P0V.4*1Y/8B:M"[H8^!+?
MKN3F&)1MK+HH*^'\!=+W1=O@GAWQ'GY?$>]9FIF[G;K-UF(;+:1>./2=([G4
MV?%V9Z@IPFOC>]JD>7BPXA[-%3"4VTR9;N(LPO9A<^N[*<FS%EE7VBNYDI"L
ML%N-)'^AQ?[EG4H/?)ZO&]_<%0/77LES*:;2M,*<)G#-K&&OA(278=\S& 7A
M&%.NY&'BZ"9<>F3;6T:.YH&6'(G&D@(^98K!E4-A#]Z7&EN_MVV9ZB^<*?3Z
MM@40:VXHL7^LQ -CNK]WZ+'QX:%3'>K13%JQ3*PW7I3EJT*$3/_R<^746UN=
MJB[&F^0:?<!S5"?4-;=Q?*":$G.3U [N\O#0"<?HVT9O4-7$\_BGQ(@77UR+
M*[9S)OR'7'AYU2MF;L\_7I[<?;YYY)K][02LV7NC[;KNGQ&7219T[9BN7+0X
M[$407K@TP@5=$_;:#&P<_"O@ Q3$N?D>@\BDCR$(-F2"+5NA;,*@"*,TTQY,
MVE!(&*7W@[AVN?,WCYZX:2UPUE8Z+%/8X!KM/=+,WJ;):FW_BM05S-Z:BGI5
M:[J59J>6K_GH3<]/-[\H5(_97U,^;X"W5?<UD8%WN;<+O9SO"C.=7R;M;1&\
MSNF8)5L_UC1L-54CW:$T6P\9.1/C%S@:\X,I$W,(:EO0F)F;MWE9HUES+F![
M$\-9GTS3>U?F"C^Y) RHV;]C:_[*;>??4$L#!!0    ( ! Y*%CORPLQ+A@
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MJZ^N7D$,NUM&38\RRLUWEV_;+Y\_W_*&^B6X^+(!>D4-V%Q64[ND2#T >.J
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MR8NH,C'GYM:(:_#6LKODS-W>];?[I,\]^MILK%73:H<1530>Q9G(1.T46S$
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M:6P^6J)49I2)'Y[*[0CN9(9O_&LI.A+T@T,O!T5Y)</7?P!02P,$%     @
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M\9J!AQ)!N-"5]#</S:0.CB>F)J;F&HQ!"(@NEYVS,^PT9CW(2DAKO@) ?8]
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MN=3QBCW&#J+<H<3R=&=_:, I"8GY#_ 5UHT0$UHYF$66#I(LDF$QNK/]<RO
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M,# W-3ED.&LN:'1M4$L! A0#%     @ $#DH6._+"S$N&   BU@  !$
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M/@  ;7)E;RTR,#(T,#$P.%]P<F4N>&UL4$L%!@     &  8 @P$  +A$
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
